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Abstract
Objective: Three common X-ray repair cross-complementing groups 1 (XRCC1) polymorphisms, Arg399Gln, Arg194Trp, and
Arg280His, have been reported to be implicated in the development of leukemia. However, previous results from different
studies were inconsistent. Consequently, we performed a meta-analysis in order to accurately evaluate the association
between XRCC1 Arg399Gln, Arg194Trp, and Arg280His polymorphisms and leukemia risk.
Methods: Through computerized searching of PubMed, ISI Web of Knowledge, Cochrane, EBSCO, and OpenGrey databases,
and manually searching relevant references, a total of 19 studies with 3387 cases and 6168 controls for Arg399Gln (G.A)
polymorphism, 12 studies with 2043 cases and 4550 controls for Arg194Trp (C.T), and 6 studies with 1445 cases and 1905
controls for Arg280His (G.A) were collected to perform meta-analysis and stratified analysis to explore the associations
between these variants and leukemia susceptibility. Based on three genetic models, the codominant model, dominant
model and recessive model, odds ratios (ORs) as well as their 95% confidence intervals (CIs) were used to evaluate the
association strength between XRCC1 genotypes and leukemia risk.
Results: With respect to overall leukemia susceptibility, no association was detected. In stratified analyses by tumor type,
Arg399Gln was associated with higher acute lymphoblastic leukemia (ALL) risk (AA vs. GG, OR = 1.50, 95% CI: 1.11-2.02;
AA+GA vs. GG, OR = 1.35, 95% CI: 1.02-1.78). Additionally, Arg399Gln, Arg194Trp, and Arg280His may influence the
susceptibilities of some leukemia type and race populations.
Conclusion: This meta-analysis indicates these three polymorphisms of XRCC1 do not associate with overall leukemia risks
but could be associated with the risks for some specific subgroups.
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Introduction
Leukemia is one of the most common human cancers, with an
estimated 48610 new cases and 23720 deaths expected in the US
in 2013 [1]. According to the cell type and growth rate, leukemia
can be classified into four groups: acute myeloid leukemia (AML),
acute lymphocytic leukemia (ALL), chronic myeloid leukemia
(CML), and chronic lymphocytic leukemia (CLL). Although
studies for leukemogenesis have been conducted for many years,
the mechanisms underlying the development of this hemotologic
malignancy remains unclear.
Impaired DNA repair may be associated with increased
susceptibility to human cancers [2]. X-ray repair cross-comple-
menting groups 1 (XRCC1) binds to DNA repair related proteins
and takes part in the DNA repair process [3,4,5]. In the past
decade, a number of studies have been performed to explore the
relationship between three common XRCC1 single nucleotide
polymorphisms (SNPs)—Arg399Gln (base G to A polymorphism),
Arg194Trp (base C to T polymorphism), and Arg280His (base G
to A polymorphism)—and leukemia risk. However, the conclu-
sions of these studies are inconsistent. Therefore, a meta-analysis
followed by stratified analysis of 19 published studies was
performed to estimate the association between XRCC1




Computer bibliographic searches through PubMed, ISI Web of
Knowledge, Cochrane, EBSCO, and grey literature database
OpenGrey were conducted using the keywords: ‘‘leukemia,’’
‘‘leukaemia’’ and ‘‘polymorphisms,’’ ‘‘genotypes,’’ ‘‘variants,’’
and ‘‘XRCC1,’’ ‘‘X-ray repair cross-complementing groups 1,’’
with the final search completed in May 2013. Studies from the
references of the related reports were checked. Articles in all
languages were searched to ensure the relevant studies were
not missed. The following inclusion criteria were applied: (1)
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case-control studies or nested case-control studies within cohort
studies, if any (2) studies evaluating association between XRCC1
polymorphism and leukemia risk, (3) full text reports which
including enough data to calculate odds ratios (ORs) and 95%
confidence intervals (CIs). The exclusion criteria were as follows:
(1) duplicated reports, (2) reviews or meta-analyses, if they were
performed without additional eligible studies; otherwise, the
additional eligible study was included in our meta-analysis, (3) if
the same population was used in multiple studies, only the most
complete or latest study was selected for further analysis.
Data extraction procedure
According to the study identification criteria, the available
studies were reviewed, selected, and the following information
from the eligible studies was extracted: first author’s last name,
publication year, country, leukemia type, number of case and
control subjects, ethnicity, control subjects source population, and
genotype numbers of cases and controls.
Study quality assessment
Critical quality assessment of the included studies was
performed by Effective Public Health Practice Project Quality
Assessment Tool (EPHPP). With this tool, assessments of the risk
of bias or methodological quality were made separately for six
individual domains: selection bias, study design, confounders,
blinding, data collection method, and withdrawals and drop-outs.
The comprehensive dictionary for the assessment tool was used to
guide the rating of the studies. Each domain was rated as strong,
moderate, or weak. The study quality was then evaluated as
strong, moderate, or weak if there were no, one, or two or more in
total weak ratings for all the domains, respectively [6]. Two
reviewers (Haijun Zhang and Hang Liu) independently reviewed
the studies and they resolved discrepancies through discussion.
Statistical analysis
Statistical analyses were performed as described previously
[7,8]. Briefly, for individual studies, Hardy-Weinberg equilibrium
of control subjects was tested by Pearson’s goodness-of-fit x2 test.
The strength of association between XRCC1 Arg399Gln,
Arg194Trp, and Arg280His polymorphisms and leukemia risk
was measured by odds ratios (ORs) and the corresponding 95%
confidence intervals (CIs). We used codominant, dominant, and
recessive genetic models to assess the pooled ORs. For both
Arg399Gln and Arg280His (G.A) polymorphisms, the codomi-
nant model included homozygous comparison of AA vs. GG and
heterozygous comparison of GA vs. GG, the dominant model was
AA+GA vs. GG, and the recessive model was AA vs. GA+GG. For
Arg194Trp (C.T) polymorphism, the codominant model includ-
ed homozygous comparison of TT vs. CC and heterozygous
comparison of CT vs. CC, the dominant model was TT+CT vs.
CC, and the recessive model was TT vs. CT+CC. Stratified
analyses were performed by race, control source, and tumor type.
Due to the high heterogeneity across the studies, the random
effects model based on the DerSimonian and Laird method was
applied [9]. For calculating the OR of a subgroup containing a
single stud, the inverse variance method was used instead.
Publication bias was evaluated by Begg’s rank correlation test
[10] and Egger’s linear regression test [11]. If the publication bias
tests indicated bias existed, the Duval and Tweedie ‘‘trim and fill’’
method was used to adjust the bias [12]. The statistical power for
XRCC1 polymorphisms and leukemia risk in three genetic models
was calculated by OpenEpi program (Version 2.3.1, www.
OpenEpi.com). Statistical analysis was conducted in R 2.15.2
using ‘‘meta’’ package [13].
Results
Study identification and characteristics of studies
Searches of PubMed, ISI Web of Knowledge, Cochrane,
EBSCO, and OpenGrey databases and manually searching
references returned 154 studies. Among them, 135 reports were
excluded for the following reasons: 55 were duplications, 42 were
irrelevant to XRCC1 polymorphisms and leukemia risk, 29 did
not provide enough genotype information, and 8 were reviews or
meta-analyses., In addition, studies that involve the same
population as another eligible study were excluded to avoid bias
[14]. Also of note was Annamaneni et al. report [15], in which the
minor allele frequencies of Arg194Trp polymorphism in both case
and control groups were much higher than major allele
frequencies, which indicated the genotype numbers of the
Arg194Trp polymorphism may include errors in this study. We
therefore excluded this study from Arg194Trp analysis. After
removing these ineligible studies, a total 19 studies with 3387 cases
and 6168 controls for Arg399Gln (G.A) polymorphism
[15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33], 12
studies with 2043 cases and 4550 controls for Arg194Trp (C.T)
[17,18,20,21,22,23,24,25,26,28,29,32], and 6 studies with 1445
cases and 1905 controls for Arg280His (G.A) [15,22,23,26,28,30]
Figure 1. Flow diagram of study identification process.
doi:10.1371/journal.pone.0080687.g001
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Table 1. Study characteristics of the meta-analysis.






source Case Control HWE QA
Arg399Gln GG GA AA GG GA AA
(G.A) Seedhouse 2002 UK Caucasian AML (167) Population 70 69 28 55 76 47 0.05 Strong
Joseph 2005 India Asian ALL (117) Hospital 55 46 16 75 33 9 0.06 Strong
Matullo 2006 Multiple Unknown Unknown
(169)
Population 67 74 28 484 482 128 0.63 Moderate
Deligezer 2007 Turkey Caucasian AML (72),
CML (182)
Population 103 121 30 96 101 29 0.76 Moderate
Pakakasama 2007 Thailand Asian ALL (108) Population 39 60 9 175 124 18 0.51 Strong
Batar 2009 Turkey Caucasian ALL (70) Population 24 37 9 24 37 14 0.97 Strong
Ganster 2009 Austria Unknown CLL (429) Population 173 192 64 184 193 52 0.90 Moderate
Meza-
Espinoza
2009 Mexico Unknown ALL (120) Population 57 51 12 65 47 8 0.90 Moderate
Tumer 2010 Turkey Caucasian ALL (167) Population 63 77 27 92 78 20 0.57 Strong
Shi 2011 China Asian AML (306) Population 173 114 19 316 213 29 0.37 Strong
Stanczyk 2011 Poland Caucasian ALL (97) Population 34 45 18 50 57 24 0.28 Moderate
Canalle 2011 Brazil Caucasian,
unknown
ALL (201) Hospital 112 72 17 186 152 23 0.27 Strong
O¨zcan 2011 Turkey Caucasian AML (36),
ALL (9)
Population 22 22 1 42 43 15 0.47 Strong
Duman 2012 Turkey Caucasian CLL (73) Population 7 50 16 19 26 5 0.36 Moderate
Kim 2012 Korea Asian AML (415) Population 234 155 26 914 693 91 0.01 Strong
Abramenko 2012 Ukraine Caucasian CLL (169) Population 67 82 20 38 41 15 0.48 Strong
El-Din 2012 Egypt Caucasian AML (40) Population 20 16 4 16 2 2 0.01 Strong
Annamaneni 2012 India Asian CML (350) Population 79 191 80 61 235 54 ,0.01 Strong
Sorour 2013 Egypt Caucasian AML (90) Population 54 27 9 33 27 0 0.02 Strong
Arg194Trp CC CT TT CC CT TT
(C.T) Seedhouse 2002 UK Caucasian AML (126) Population 112 14 0 78 7 2 ,0.01 Strong
Joseph 2005 India Asian ALL (117) Hospital 77 32 8 91 22 4 0.09 Strong
Matullo 2006 Multiple Unknown Unknown
(169)
Population 145 23 1 951 141 2 0.17 Moderate
Pakakasama 2007 Thailand Asian ALL (108) Population 62 44 2 150 145 22 0.10 Strong
Batar 2009 Turkey Caucasian ALL (70) Population 52 16 2 64 11 0 0.49 Strong
Ganster 2009 Austria Unknown CLL (439) Population 371 63 5 389 45 5 0.01 Moderate
Meza-
Espinoza
2009 Mexico Unknown ALL (120) Population 80 34 6 86 31 3 0.92 Moderate
Tumer 2010 Turkey Caucasian ALL (167) Population 140 27 0 159 26 5 0.01 Strong
Canalle 2011 Brazil Caucasian,
unknown
ALL (201) Hospital 168 32 1 298 59 4 0.58 Strong
Duman 2012 Turkey Caucasian CLL (73) Population 64 8 1 41 9 0 0.48 Moderate
Kim 2012 Korea Asian AML (413) Population 167 208 38 775 741 164 0.50 Strong
El-Din 2012 Egypt Caucasian AML (40) Population 11 14 15 14 4 2 0.09 Strong
Arg280His GG GA AA GG GA AA
(G.A) Joseph 2005 India Asian ALL (117) Hospital 76 38 3 85 30 2 0.73 Strong
Pakakasama 2007 Thailand Asian ALL (108) Population 94 14 0 272 42 3 0.34 Strong
Ganster 2009 Austria Unknown CLL (443) Population 396 47 0 388 53 2 0.90 Moderate
Meza-
Espinoza
2009 Mexico Unknown ALL (120) Population 87 31 2 88 31 1 0.33 Moderate
Shi 2011 China Asian AML (307) Population 236 66 5 445 109 4 0.34 Strong
Annamaneni 2012 India Asian CML (350) Population 346 4 0 338 11 1 0.01 Strong
AML, acute myeloid leukemia; ALL, acute lymphocytic leukemia; CML, chronic myeloid leukaemia; CLL, chronic lymphocytic leukemia; HWE, P value of Pearson’s
goodness-of-fit x2 test for Hardy-Weinberg equilibrium; QA, quality assessment; Unknown, including study populations in which the race was mixed/unclear or tumor
type was not described.
doi:10.1371/journal.pone.0080687.t001
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were included for further analysis (Figure 1). A database was
established to display the study characteristics of each eligible
study (Table 1). The distribution of genotypes in the control group
of each study was in agreement with Hardy-Weinberg equilibrium
except for 4 studies for Arg399Gln, 3 studies for Arg194Trp and 1
study for Arg280His (Table 1). All the included studies were rated
as strong or moderate by EPHPP Quality Assessment Tool,
indicating that the synthesis of results in a meta-analysis should be
reliable (Table 1).
Meta-analysis results
Meta-analysis and relevant subgroups analysis by tumor type,
race and control sources were conducted to examine the
association between XRCC1 Arg399Gln (G.A), Arg194Trp
(C.T), and Arg280His (G.A) polymorphisms and leukemia risk
in three genetic models. Stratified analysis by race and control
sources in each leukemia type and by etiology in AML was further
performed to explore the possible associations. The analyses results
were shown in Table 2. The statistical power for XRCC1
polymorphisms and leukemia risk in three genetic models was
shown in Table 3.
XRCC1 Arg399Gln (G.A) polymorphism
In the overall analysis, no statistically significant association
between XRCC1 Arg399Gln polymorphism and leukemia
susceptibility was observed in three genetic models. A very mild
publication bias was detected by Egger’s test (P = 0.04; Begg’s
test, P = 0.12) in the codominant heterozygous comparison (GA
vs. GG) (other data not shown). We repeated meta-analysis with
the ‘‘trim and fill’’ method to adjust publication bias in this genetic
model. The conclusion was not influenced, which indicated the
robustness our conclusions (data not shown). In the stratified
analysis by racial descent, increased risk of leukemia was found
among Asians (AA vs. GA+GG, OR = 1.42, 95% CI: 1.12-1.81),
and the unknown or mixed race subgroup (AA vs. GG, OR =
1.44, 95% CI: 1.07-1.93; AA vs. GA+GG, OR = 1.39, 95% CI:
1.06-1.84).
When performing meta-analysis by tumor type, higher risk can
be detect in ALL (AA vs. GG, OR = 1.50, 95% CI: 1.11-2.02;
AA+GA vs. GG, OR = 1.35, 95% CI: 1.02-1.78) (Figure 2A and
2B) and among ALL Asian (AA vs. GG, OR = 2.33, 95% CI:
1.25-4.34; GA vs. GG, OR = 2.06, 95% CI: 1.44-2.95; AA+GA
vs. GG, OR = 2.11, 95% CI: 1.50-2.97) and population-based
control subgroups (AA vs. GG, OR = 1.47, 95% CI: 1.02-2.11;
GA vs. GG, OR = 1.45, 95% CI: 1.15-1.83; AA+GA vs. GG,
OR = 1.45, 95% CI: 1.13-1.85). Although significant association
was not found in AML, CML and CLL and in most subgroups by
race and control sources of these leukemia types, a protective effect
was exhibited among the secondary and therapy-related AML (AA
vs. GG, OR = 0.30, 95% CI: 0.11-0.82; AA+GA vs. GG, OR =
0.53, 95% CI: 0.31-0.89) and the CML Asian subjects (GA vs.
GG, OR = 0.63, 95% CI: 0.43-0.92; AA vs. GA+GG, OR =
1.62, 95% CI: 1.11-2.38).
XRCC1 Arg194Trp (C.T) polymorphism
XRCC1 Arg194Trp was not associated with the leukemia
susceptibility in the overall population or in different race and
control source subgroups. Publication bias does not exist across the
studies (data not shown). Arg194Trp worked as a risk factor in the
AML Asians (CT vs. CC, OR = 1.30, 95% CI: 1.04-1.63;
TT+CT vs. CC, OR = 1.26, 95% CI: 1.01-1.57) albeit there was
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XRCC1 Arg280His (G.A) polymorphism
As for Arg280His polymorphism, no statistically significant
association was present in any genetic model or subgroup except
for among the secondary and therapy-related AML codominant
model homozygous comparison (AA vs. GG, OR = 8.90, 95%
CI: 1.56-50.94), and the recessive model (AA vs. GA+GG, OR =
8.15, 95% CI: 1.44-46.06). Begg’s test and Egger’s test showed
publication bias in the main meta-analysis in the codominant
homozygous comparison (AA vs. GG, Begg’s test P = 0.04,
Egger’s test P = 0.02), and the recessive model (AA vs. GA+GG,
Begg’s test P = 0.04, Egger’s test P = 0.02) (other data not
shown). Adjusting these two models by ‘‘trim and fill’’ method did
not influence the conclusion (data not shown).
Discussion
Nonsynonymous XRCC1 polymorphisms Arg399Gln,
Arg194Trp, and Arg280His have been implicated in the risk of
various cancers [7,8,34]. The relationship between these XRCC1
polymorphisms and leukemia risk has been examined in some
case--control studies, but the results of these studies were
contradictory and inconclusive. Although the association between
XRCC1 polymorphisms and risk of some types of leukemia was
recognized by a number of studies [15,17,20,21,22,23,24,25,27,
28,29,32,33], other reports did not take the XRCC1 genetic
variants as risk or protective factors for leukemia
[16,18,19,26,30,31]. We conducted a meta-analysis that includes
19 studies for Arg399Gln (G.A) polymorphism, 12 studies for
Arg194Trp (C.T), and 6 studies for Arg280His (G.A) to
evaluate XRCC1 genotype-leukemia association (Figure 1).
Although associations between Arg399Gln, Arg194Trp, and
Arg280His and overall leukemia risks were lacking, higher
leukemia susceptibility was detected for Arg399Gln among Asians
(AA vs. GA+GG, OR = 1.42, 95% CI: 1.12-1.81), and the
unknown or mixed race subgroup (AA vs. GG, OR = 1.44, 95%
CI: 1.07-1.93; AA vs. GA+GG, OR = 1.39, 95% CI: 1.06-1.84)
while no such effect was found among Caucasians (Table 2). The
finding in Asians is consistent with previous studies that the
Arg399Gln polymorphism increases glioma risk among Asians [8]
but does not alter glioma [8] or skin cancer [7] risks among
Caucasians, which indicates a race-specific effect of this polymor-
phism in some tumors. The analysis for unknown or mixed
population implies that, excepting Caucasians, other races in these
populations may be sensitive to Arg399Gln associated leukemia
risk. Collecting more samples from races other than Asian and
Caucasian will be necessary to verify the conclusion in future
studies.
The predisposition of each leukemia type could be differentially
influenced by genetic factors. We performed stratified analysis by
leukemia type in order to clarify the role of XRCC1 polymor-
phisms in the development of individual types of leukemia (Table
2). In the secondary and therapy-related AML, Arg399Gln is a
protective factor (AA vs. GG, OR = 0.30, 95% CI: 0.11-0.82;
AA+GA vs. GG, OR = 0.53, 95% CI: 0.31-0.89) whereas
Arg280His is a risk factor (AA vs. GG, OR = 8.90, 95% CI: 1.56-
50.94; AA vs. GA+GG, OR = 8.15, 95% CI: 1.44-46.06). The
occurrence of secondary and therapy-related AML is correlated
with prior chemotherapy and/or radiation therapy, which
probably involves XRCC1 mediated DNA repair. XRCC1
polymorphisms could alter the susceptibility of this AML category
by changing XRCC1 DNA repair capacity. However, only one or
two studies were included in these subgroups, which compromises
the reliability of these findings. Arg399Gln increases CML risk
Table 3. Statistical power (%) for XRCC1 polymorphisms and leukemia risk.
Polymorphism
Homozygous
codominant Heterozygous codominant Dominant Recessive
Arg399Gln (G.A) AA vs. GG GA vs. GG AA+GA vs. GG AA vs. GA+GG
100 80.4 98.8 99.8
Arg194Trp (C.T) TT vs. CC TC vs. CC TT+TC vs. CC TT vs. TC+CC
36.7 50.4 65.4 30.1
Arg280His (G.A) AA vs. GG GA vs. GG AA+GA vs. GG AA vs. GA+GG
1.1 8.0 7.9 1.1
doi:10.1371/journal.pone.0080687.t003
Figure 2. Forest plots showed meta-analysis of XRCC1
Arg399Gln polymorphism and acute lymphocytic leukemia
(ALL) risk in (A) homozygous codominant (AA vs. GG), and (B)
dominant (AA+GA vs. GG) models. OR, Odds ratio; CI, confidence
interval.
doi:10.1371/journal.pone.0080687.g002
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(GA vs. GG, OR = 0.63, 95% CI: 0.43-0.92; AA vs. GA+GG,
OR = 1.62, 95% CI: 1.11-2.38), and Arg194Trp increases AML
risk (CT vs. CC, OR = 1.30, 95% CI: 1.04-1.63; TT+CT vs. CC,
OR = 1.26, 95% CI: 1.01-1.57) among Asians. The conclusions
are both derived from one single study and need to be interpreted
carefully. Arg399Gln is associated with higher risk in ALL (AA vs.
GG, OR = 1.50, 95% CI: 1.11-2.02; AA+GA vs. GG, OR =
1.35, 95% CI: 1.02-1.78) (Figure 2A and 2B) and among ALL
Asian (AA vs. GG, OR = 2.33, 95% CI: 1.25-4.34; GA vs. GG,
OR = 2.06, 95% CI: 1.44-2.95; AA+GA vs. GG, OR = 2.11,
95% CI: 1.50-2.97) and ALL population-based control subgroups
(AA vs. GG, OR = 1.47, 95% CI: 1.02-2.11; GA vs. GG, OR =
1.45, 95% CI: 1.15-1.83; AA+GA vs. GG, OR = 1.45, 95% CI:
1.13-1.85). The results from population-based and hospital-based
studies are different. The former may be more reliable since
patient controls usually carry other disease conditions, which
might potentially influence leukemia risk.
The advantages of this meta-analysis are that it is the most
complete and the information from the eligible studies is utilized as
much as possible through genetic model and stratified analysis.
However, there are several limitations in this study. First,
expression of specific genes is highly regulated by a transcriptional
control mechanism requiring transcription factors-gene promoter
interaction [35,36,37,38]. XRCC1 -77 T.C polymorphism might
change the binding capacity of the transcription factor SP1 to the
XRCC1 promoter, and then downregulate XRCC1 expression
[39]. This polymorphism contributes to the development of lung
cancer [40] and breast cancer [39]. However, studies addressing
the association between XRCC1 -77 T.C polymorphism and
leukemia risk are absent, and cannot be analyzed by our meta-
analysis. In addition to the promoter control, the regulation of 3’
untranslated region (3’UTR), by regulators for example micro-
RNAs, influences gene expression in cancer and developmental
process [41,42]. However, whether the XRCC1 polymorphisms in
3’UTR alter leukemia risk was not fully studied. Second, although
the statistical power for Arg399Gln was greater than 80% in all
three genetic models, the power for Arg194Trp and Arg280His
was not as high as that in Arg399Gln (Table 3). The lower power
for these two polymorphisms indicates that the weak associations
between Arg194Trp and Arg280His and leukemia risk might not
be detected while the associations that are detected in our meta-
analysis still remain interesting. Statistical power in the genetic
association study is primarily affected by the participant numbers
and the effect size (OR) when choosing conventional level of a
significance criterion 0.05 in the target population. Because the
effects of the Arg194Trp and Arg280His polymorphisms on
leukemia risk are weak (Table 2, ORs are close to 1), further study
with larger sample numbers will be helpful to improve the power
for detecting the positive effects. To the current meta-analysis, the
negative association between these two polymorphisms and
leukemia susceptibility should be cautiously interpreted. Third,
the eligible study number for some individual subgroups is small,
which restricts the application of the conclusions drawn from those
subgroups. Fourth, four eligible studies contained an "unknown"
race population. Specific race information was not collect by two
of them [22,25]. The other two studies included non-Caucasian
mestizos or mulattos [18,26]. Since the ethnicities of mestizos and
mulattos were difficult to determine, we then described the non-
Caucasian population in these two studies as "unknown" race. We
have discussed the necessity of performing study with different
races in the future studies according to the findings from the
unknown population. In the report of Matullo et al. [25],
information about the leukemia subtype was not presented. The
purpose of the original study was not to conduct a detailed analysis
of the subtypes of leukemia. In addition to leukemia, multiple types
of cancer as well as emphysema and chronic obstructive
pulmonary disease were evaluated based on the data collected
by 23 centers from 10 countries. It would be difficult for the
researchers to extract the detailed subtype information for a single
cancer type, for example leukemia, after the study have been
completed. Moreover, the case numbers of this study were not
very large; thus the study would not strongly affect the outcome of
our subgroup analysis by tumor type of leukemia. Accordingly, we
did not use the leukemia tumor type information of this study in
our meta-analysis. Finally, African populations have not been well
studied previously regarding XRCC1 polymorphisms and leuke-
mia susceptibility. Data from this population will be useful to
establish a better overview of polymorphism-leukemia association.
Taken together, results from this meta-analysis demonstrate that
XRCC1 Arg399Gln, Arg194Trp and Arg280His polymorphisms
might not be associated with overall leukemia risk. However, these
polymorphisms might potentially be protective factors or risk
factors in specific leukemia types or among particular ethnicities.
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